News from orexo A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 02, 2017, 02:30 ET Orexo Receives USD 2.5 Million Milestone Payment From AstraZeneca as OX-CLI Advances Into Clinical Trials

Orexo AB (publ.) today announced that the OX-CLI project has advanced into clinical phase I triggering a milestone payment of USD 2.5 million´(approx....

Apr 20, 2017, 02:13 ET Orexo - Interim Report Q1 2017

Financial overview Q1 2017 Total net revenues SEK 127.4 million (151.0) Zubsolv® net revenue SEK 114.1 million (98.4) EBIT SEK -23.2 million (-26.2)...

Apr 06, 2017, 12:41 ET Report From Orexo AB´s Annual General Meeting, April 6 2017

Election of the board of directors and auditor The annual general meeting in Orexo AB (publ) on April 6 2017 resolved, in accordance with the...

Mar 07, 2017, 03:43 ET Notice of Annual General Meeting of Orexo

The shareholders in Orexo AB (publ.) are summoned to the annual general meeting, to be held on Thursday 6 April 2017, at 4.00 pm in Orexo's...

Mar 01, 2017, 01:55 ET Orexo Commences Patent Infringement Litigation Against Actavis for Their Generic Versions of Suboxone® and Subutex® Tablets in the US

Orexo AB (publ.) today announced that it has filed a patent infringement action in United States District Court for the District of Delaware against...

Feb 20, 2017, 01:07 ET Orexo Completes Bond Buyback Program

Orexo AB (publ.) announces that it has successfully completed a limited bond buyback program and in total purchased Orexo corporate bonds in the...

Jan 31, 2017, 10:56 ET Number of Shares and Votes in Orexo

The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company's incentive programs....

Jan 26, 2017, 01:18 ET Orexo - Full Year Report 2016

2016 - First profitable year Fourth quarter 2016 Total net revenues MSEK 184.7 (228.3) Zubsolv® net revenue MSEK 128.2 (120.3) Net earnings MSEK 33.3 ...

Dec 21, 2016, 02:49 ET Orexo Completes Bond Buyback Program

Orexo AB (publ.) announces that it has successfully completed a bond buyback program and in total purchased Orexo corporate bonds in the market with...

Dec 08, 2016, 02:18 ET Orexo Appeal Zubsolv® US District Court Decision

Orexo AB (publ.) announces that it has appealed the decision rendered by the United States District Court for the District of Delaware on November...

Oct 06, 2016, 08:00 ET U.S. FDA Approves Orexo's Low Dose ZUBSOLV® Buprenorphine and Naloxone Sublingual Tablets (CIII)

Orexo US announced today that the U.S. Food and Drug Administration (FDA) has approved ZUBSOLV® (buprenorphine/naloxone CIII sublingual tablet)...

Jul 25, 2016, 11:29 ET Orexo Applauds Historic Signing of Landmark Comprehensive Addiction & Recovery Act

Orexo US, Inc. applauds the historic signing of the Comprehensive Addiction & Recovery Act of 2016 (CARA), S.524. CARA will play a critical role in...